Tafluprost (DrugBank: Tafluprost)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 299 | 嚢胞性線維症 | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-004302-26-SK (EUCTR) | 22/04/2016 | 26/01/2016 | Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed. | A phase I study to evaluate the pharmacokinetics, safety and tolerability of preservative free tafluprost ophthalmic solution (0.0015%) in pediatric patients diagnosed with glaucoma or ocular hypertension. - Phase I Study to Evaluate Tafluprost Eye Drops in Paediatric Patients. | Glaucoma or Ocular Hypertension MedDRA version: 18.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Tafluprost INN or Proposed INN: tafluprost Other descriptive name: TAFLUPROST | Santen Oy | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 1 | United States;Hungary;Slovakia;Poland;United Kingdom | ||
| 2 | EUCTR2013-004302-26-HU (EUCTR) | 29/02/2016 | 21/12/2015 | Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed. | A phase I study to evaluate the pharmacokinetics, safety and tolerability of preservative free tafluprost ophthalmic solution (0.0015%) in pediatric patients diagnosed with glaucoma or ocular hypertension. - Phase I Study to Evaluate Tafluprost Eye Drops in Paediatric Patients. | Glaucoma or Ocular Hypertension MedDRA version: 18.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Tafluprost INN or Proposed INN: tafluprost Other descriptive name: TAFLUPROST | Santen Oy | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 1 | United States;Hungary;Slovakia;Poland;United Kingdom | ||
| 3 | EUCTR2013-004302-26-GB (EUCTR) | 05/09/2014 | 01/05/2014 | Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed. | A phase I study to evaluate the pharmacokinetics, safety and tolerability of preservative free tafluprost ophthalmic solution (0.0015%) in pediatric patients diagnosed with glaucoma or ocular hypertension. - Phase I Study to Evaluate Tafluprost Eye Drops in Paediatric Patients. | Glaucoma or Ocular Hypertension MedDRA version: 18.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Santen Oy | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 1 | United States;Hungary;Slovakia;Poland;United Kingdom |